– Exclusive worldwide license agreement for
antibodies against undisclosed target
JERUSALEM, July 25,
2024 /PRNewswire/ -- Nectin Therapeutics, Ltd., a
biotechnology company developing novel immunotherapies and
antibody drug conjugates (ADC) to address tumor resistance, today
announced a global, exclusive license agreement with Immunome Inc.
(Nasdaq: IMNM), a biotechnology company focused on developing
first-in-class and best-in-class targeted cancer therapies. Under
the terms of the license, Immunome received exclusive rights to a
panel of antibodies targeting an undisclosed target.
"This agreement allows Nectin to realize value while further
pursuing and enabling the focus on our first-in-class anti-PVR
program (NTX1088) through its ongoing clinical study in tumor types
with high unmet need as well as advance our novel ADCs into
clinical development. Immunome's leadership team's track record of
developing and commercializing novel ADC therapies makes it an
ideal partner to advance these promising assets," said Fabian Tenenbaum, Chief Executive Officer of
Nectin Therapeutics.
"Immunome believes the next generation of transformative
antibody drug conjugates will address novel targets by pairing
high-quality antibodies with innovative linker-payload technology,"
said Clay Siegall, PhD, President
and Chief Executive Officer of Immunome. "We appreciate the work
Nectin has done on these antibodies and look forward to advancing
them further."
Under the terms of the agreement, Nectin granted
Immunome an exclusive, worldwide, all-fields license to
monoclonal antibodies that are directed to a single undisclosed
target. Immunome will be responsible for the research,
development, manufacturing and commercialization of
products incorporating these antibodies. Nectin will receive
an upfront payment and will be eligible for milestones and
royalties.
About Nectin Therapeutics, LTD.
Nectin Therapeutics is a clinical stage biotechnology company
devoted to transforming the lives of cancer patients by leveraging
unique insights into Nectin pathways to develop the next generation
of immune oncology (IO) therapies and antibody drug conjugates
(ADCs). The company's differentiated therapies have the potential
to set new standards for efficacy and patient response rates across
various difficult-to-treat cancers. Nectin's technology addresses
major escape mechanisms of current IO therapies through a diverse
pipeline of novel monoclonal antibodies and antibody drug
conjugates (ADCs). It has a world-class scientific and management
team with deep experience in oncology drug development and
successful track records in building biotechnology companies and
developing innovative therapies. Nectin Therapeutics is a
venture-backed, privately held company, funded by aMoon Fund,
Peregrine Ventures, IBF, Integra Holdings, the Myeloma Investment
Fund (MIF), GIBF and the Cancer Focus Fund.
Nectin Contact:
Fabian Tenenbaum
Chief Executive Officer
info@nectintx.com
+1 201 218-1774
View original
content:https://www.prnewswire.com/news-releases/nectin-therapeutics-licenses-novel-antibodies-to-immunome-302206469.html
SOURCE Nectin Therapeutics